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This special supplement of the Journal of Cystic Fibrosis
is the second of two supplements dedicated to the European
Coordination Action for Research in Cystic Fibrosis (Euro-
CareCF) project. Funded by the Sixth Framework Programme
of the European Commission, EuroCareCF provided individ-
uals working to defeat the common, life-shortening, genetic
disease cystic ﬁbrosis (CF) with opportunities to interact,
exchange information and collaborate to achieve common
goals. The major goals of the project were ﬁrst, to improve
the survival and quality of life of CF patients and second, to
optimize clinical management and therapy development.
To achieve its goals, EuroCareCF was organized into a
series of eight workpackages addressing different areas of CF
research and patient care (Fig. 1). These areas ranged from
basic research and therapy development to clinical research,
patient care and the development of a European CF patient
registry. Through a variety of activities, such as meetings,
workshops and “hands-on” training courses, workpackages
produced reports and consensus guidelines, built networks of
CF professionals, provided expert training and distributed key
resources to the CF community. Some reports and consensus
guidelines have already been published (e.g. [1–3]), while
others will be published separately (e.g. [4]). However, the
majority are published in this supplement to the Journal of
Cystic Fibrosis.
A further supplement is devoted to the report of Euro-
CareCF workpackage 2 (European CF Patient Registry) on
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the demographics of CF in 35 European countries [5]. This
report is the culmination of work to create a uniform and
ethically compliant European registry of CF patients. Through
collaboration with the European Cystic Fibrosis Society
(ECFS), the scope of the original Registry was enlarged sub-
stantially to include CF patients from all countries in Europe,
member and non-member states of the European Union alike.
A special feature of the EuroCareCF workpackage 2 report
[5] is that demographic data for individual countries in Europe
are compared side-by-side with demographic data for all of
Europe (i.e. 29,095 patients from 35 countries).
The consensus guidelines and reports published in this
supplement reﬂect in full the wide-ranging remit of the Eu-
roCareCF project. For example, in a report for EuroCareCF
workpackage 1 (Optimising Patient Care & CF Team Work),
Colombo and Littlewood [6] discuss the implementation in
Europe of the ECFS Standards of Care for CF patients [7].
Colombo and Littlewood [6] make a number of recommen-
dations for improving CF patient care including the delivery
of CF patient care by multidisciplinary teams specializing in
CF patient care adequately funded to deliver such care. Fur-
thermore, EuroCareCF workpackage 1 produced additional
guidelines for CF patient care to augment the ECFS Standards
of Care for CF patients [7], including consensus statements
on CF bone disease validated by Delphi methodology [8]
and advice on the delivery of psychological support for CF
patients [9].
By themselves, the consensus guidelines and reports pro-
duced by EuroCareCF workpackage 3 (Coordination of
Clinical Research) cover a wide spectrum of clinical research
including the diagnosis of CF and cystic ﬁbrosis trans-
membrane conductance regulator (CFTR)-related diseases,
neonatal screening, microbiology and clinical trials. The
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Fig. 1. The organization of the EuroCareCF project. EuroCareCF consisted of eight workpackages undertaking programmes of work to address speciﬁc aspects
of patient care and therapy development and a coordinating workpackage that managed the project, promoted interactions between project participants and
stakeholders and communicated with the European Commission (EC). The eight workpackages of EuroCareCF were Optimising Patient Care & CF Team
Work; European Cystic Fibrosis Patient Registry; Coordination of Clinical Research; Small and Medium-Sized Enterprises (SMEs) Group; Novel Therapies;
Animal Models; Integration of Fundamental Research and Ethical/Legal/Social Issues.
EuroCareCF consensus guidelines on neonatal screening [1]
were published in the Journal of Cystic Fibrosis in 2009, while
the microbiology guidelines will be published separately in a
forthcoming issue of the Journal. The EuroCareCF report on
CFTR-related diseases [10] breaks new ground by identifying
clinical conditions associated with CFTR dysfunction, which
do not fulﬁll the diagnostic criteria for CF. This report is
the result of passionate debate by a wide range of specialists
including clinicians, geneticists and basic scientists. Claude
Ferec deserves special thanks for his efforts to coordinate the
EuroCareCF report on CFTR-related diseases [10]. We can
be conﬁdent that as knowledge and understanding of CFTR
dysfunction in CF and CFTR-related diseases evolves, the di-
agnosis and management of individuals with these conditions
will witness further signiﬁcant advances.
De Boeck et al. [11] describe the pivotal role played by
EuroCareCF workpackage 3 in the development of the ECFS
Clinical Trials Network (ECFS-CTN), reviewing the rationale
for the ECFS-CTN, its organization and operation. Together
with the US Cystic Fibrosis Foundation Therapeutics De-
velopment Network, there is now the exciting possibility of
coordinating US and European clinical trials of new ther-
apies for CF to accelerate drug development and approval.
To facilitate the activities of the ECFS-CTN, EuroCareCF
workpackage 3 developed a number of consensus documents
on outcome measures in clinical trials (e.g. pulmonary exac-
erbation [12]) and produced an exhaustive review of efforts
to standardize the nasal potential difference and intestinal
current measurement assays in European laboratories for the
purpose of diagnosing CF, CFTR-related diseases and evalu-
ating new therapies in the clinic [13] (for further information
on measuring intestinal current in rectal biopsies, see the
EuroCareCF workpackage 7 (Integration of Fundamental Re-
search) report [4]). Undoubtedly, these initiatives will improve
the performance of CF clinical trials and enhance the quality
of data generated.
Efforts to optimize therapy development are the focus of
consensus guidelines and reports produced by EuroCareCF
workpackage 4 (Small and Medium-Sized Enterprises (SMEs)
Group) and workpackage 5 (Novel Therapies). In a report for
EuroCareCF workpackage 4, Schlangen and Reimann [14]
discuss the considerable challenges that SMEs face develop-
ing new therapies for CF patients. Besides those challenges
identiﬁed by other EuroCareCF workpackages, Schlangen and
Reimann [14] draw attention to the regulation of market
authorization by national and supranational agencies. The au-
thors highlight the special needs of SMEs working to develop
new therapies for rare diseases with small patient popula-
tions and urge the harmonization of regulatory requirements
between different agencies [14]. The reports of EuroCareCF
workpackage 5 [15–17] review the development of (i) gene
and cell therapies, (ii) antibiotics and (iii) pharmacological
therapies based on a rational understanding of CFTR dysfunc-
tion in CF. In all three areas, there are common and distinct
challenges to translating discoveries in the laboratory to the
clinic. The reports of EuroCareCF workpackage 5 [15–17]
provide a thorough review of drug development strategies in
each of the three different areas
EuroCareCF workpackage 6 (Animal Models) contributes
two reports to this supplement on mouse models of CF.
Zhou et al. [18] demonstrate that mice overexpressing the β
subunit of the epithelial Na+ channel (βENaC-overexpressing
mice) are an effective model of CF lung disease. These mice
are a valuable tool to investigate strategies to restore airway
surface ﬂuid and target mucus obstruction and inﬂammation
in early and chronic lung disease. Wilke et al. [19] revel
in the lessons learnt from genetically-engineered mice about
the varied physiological roles of CFTR. After white teeth,
disﬁgured tracheal cartilage and ﬂaccid diaphragm muscles
what further surprises await discovery in these mice? Oh,
itchy skin [20]! Together, the EuroCareCF workpackage 6
reports [18,19] demonstrate convincingly the continued value
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of CF mouse models to elucidate disease pathogenesis and
evaluate experimental therapeutics.
The EuroCareCF workpackage 8 (Ethical/Legal/Social
Issues) report [21] analyses national and supranational leg-
islation in the European Union governing the conduct of
paediatric clinical trials. Pinxten et al. [21] make a number of
recommendations for the conduct of clinical trials involving
CF minors. These include (i) shared responsibility for the
ethical conduct of clinical trials; (ii) effective communication
with minors and their parents (or legal representatives); (iii)
the minor is the focal point of all consent discussions irrespec-
tive of their degree of maturity; (iv) no one CF minor should
participate too frequently in clinical trials; (v) the interpreta-
tion of legislation by clinicians should be a group decision;
(vi) safeguards are required to protect the trust between clin-
icians, minors and their parents (or legal representatives) and
(vii) ethics committees should be expert in the ethical, legal
and social issues associated with paediatric clinical trials. The
full implementation of the EuroCareCF workpackage 8 report
[21] will lead to paediatric clinical trials being conducted to a
higher ethical standard.
Taken together, the EuroCareCF consensus guidelines and
reports provide invaluable guidance for patient care and
therapy development. This information is relevant not just to
CF, but also to other rare diseases. By working together and
sharing information, everybody wins, most of all individuals
afﬂicted by genetic diseases.
Finally, I would like to take this opportunity to thank
many wonderful colleagues for their wide-ranging contribu-
tions to the success of the EuroCareCF consensus guidelines
and reports. Margarida Amaral, Carla Colombo, Anil Mehta,
Kris De Boeck, Andreas Reimann, Massimo Conese, Bob
Scholte, Burkhard Tümmler, Dorota Sands, Milan Macek
Jr, Peter Vandamme, Pier Franco Pignatti, Frédéric Becq,
Robert Bals, William Colledge, Marcus Mall, Martin Hug,
Kris Dierickx and Herman Nys for organizing the various
reports and consensus guidelines. With tireless enthusiasm,
commitment and dedication, they arranged meetings, led
discussions, drafted and revised manuscripts until consensus
agreement was reached. All participants of the different meet-
ings and workshops, especially the authors of the different
consensus guidelines and reports for their active contribution
to the project. The expert referees for their careful review
of the manuscripts and thoughtful comments, which have
enhanced the quality of the reports and consensus guidelines.
Gerd Döring, Marie Johannesson and Stuart Elborn, past
and present presidents of the ECFS for their unwavering
support of the EuroCareCF project and Christine Dubois and
Sarah Young for their efﬁcient help organizing EuroCareCF
meetings at ECFS conferences. Cooperation from national
CF societies and CF Europe. Members of the EuroCareCF
Advisory Committee for their wise council, especially Jean-
Jacques Cassiman for his invaluable guidance when preparing
the EuroCareCF application for submission to the European
Commission. Gerd Döring, Editor-in-Chief of the Journal of
Cystic Fibrosis for his enthusiastic support for the publication
of the EuroCareCF reports and consensus guidelines in the
Journal. Nick Dunwell, Eva Nagtegaal and their colleagues at
Elsevier. Finally, Gita Mehta, Hongyu Li and Vicky Nelson
for excellent project management and administrative support
to this complex project.
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